RADIENT PHARMACEUTICALS CORPORATION

Douglas C. MacLellan is Chairman of the Board of Directors and Chief Executive Officer of AMDL Inc. a US-based pharmaceutical company with major operations in China.

Through MacLellan’s leadership, AMDL is on an aggressive growth trajectory, expanding from a China-only focused pharmaceutical company to an emerging international leader that offers a broad portfolio of diagnostic, pharmaceutical and cosmetic products.

MacLellan has been a member of AMDL’s Board of Directors since 1992, previously serving as Chairman of the Company's audit and governance committees. With more than twenty-five years international business management and active board experience, MacLellan has been a catalyst for the development, growth and success of many public and privately-held businesses worldwide. Additionally, MacLellan has extensive business management experience in the People’s Republic of China, where he has been actively involved since 1983. He is a recognized authority on Chinese joint venture and wholly foreign owned enterprise (WFOE) structuring and considered an expert on the China government and regulator and compliance system.

Throughout his professional career, MacLellan has served on the board of 18 separate companies where he has played an instrumental role in strategic planning, general operations, corporate finance activities, economic policy, asset allocation and mergers & acquisitions. In addition, he has supported the raise of over US$715 million in capital for development stage, start-up and mid-cap companies.

Additional companies MacLellan has served in leadership roles include, MacLellan Group, Inc., a privately held business incubator and financial advisory firm MacLellan founded in 1992; Board member of Edgewater Foods, International, Inc.; Vice-Chairman of the Board of AXM Pharma, Inc. (AMEX: AXJ) a China based bio-pharmaceutical company; Vice-Chairman of Asia American Telecommunications (now Metromedia China Corporation), a majority owned subsidiary of Metromedia International Group, Inc.; Co-Chairman and Investment Committee member of the Strategic East European Fund; President, Chief Executive Officer and Director of PortaCom Wireless, Inc. a company engaged as a developer and operator of cellular and wireless telecommunications ventures in selected developing world markets; Board member and co-founder of FirstCom Corporation an international telecommunications company that operates an access fiber and satellite network in Latin America (now AT&T Latin America); and Principal and co-founder of Maroon Bells Capital Partners, Inc. U.S. based merchant bank specializing corporate finance services for international and domestic telecommunications and media companies.

MacLellan received advanced training in classical economic theory and international relations from the University of Southern California and was a student of Arthur Laffer, Ph.D., who later employed him as an economist. Mr. MacLellan has also authored numerous industry-specific research papers and portfolio strategy and economic forecasts over the past 25 years.

Mr. Boswell is a co-founder of the TriPoint family of companies and co-founder and member of TriPoint Capital Advisors, LLC, a boutique merchant bank focused on small and mid-sized growth companies. Specifically active with companies in "The Republic of China", Mr. Boswell provides high-level financial services and executive guidance to start-up businesses and small to mid-sized companies. Currently he is acting CFO and director of Edgewater Foods International (OTCBB: EDWT), and a financial advisor and consultant to Tianyin Pharmaceutical Co, Inc. (AMEX: TPI) and JPAK Group Inc. (OTCBB: JPAK). He is a recognized expert in corporate finance, structure and governance; mergers and acquisitions; SOX 404 compliance; SEC rules, reporting and disclosure; FASB Emerging Issues Task Force issues specifically as they relate to private placements; employee option programs; and the reverse merger strategy and process.

Prior to co-founding the TriPoint family of companies, Mr. Boswell held various executive positions with business development and management consulting firms. Mr. Boswell holds the Series 24, 82 and 63 licenses and is COO of TriPoint Global Equities**. Mr. Boswell also spent eight years as a senior analyst and senior engineer in various branches of the United States Government. He earned a MBA from John Hopkins University and a BS degree in Mechanical Engineering from University of Maryland.

William M. Thompson III, M.D., J.D. has been one of our directors since June 1989, Chairman since 1991, and he was CEO in 1992-4. Dr. Thompson has practiced medicine for over 40 years, in general practice, general surgery and trauma surgery.

Previously, he had practiced patent law, and he worked in the pharmaceutical industry, in research, law and senior management for 13 years. During his medical career, he was founding Medical Director of Beech Street and August Healthcare Companies in a 25-year association with the managed care (PPO) industry. Also, he served on the OSCAP Board of SCPIE, the malpractice insurance carrier, for 20 years, and chaired its Claims Committee for many years. In addition, he has been heavily involved over many years with organized medicine and with hospital medical staff management. Moreover, he was a principal architect of the paramedic and emergency medical systems of Orange County, CA. He has been a member of the clinical surgical faculty at UCI School of Medicine for over 30 years. Also, he is currently Medical Director of PPO Next.

Edward R. Arquilla, M.D. Ph.D., has been a member of the Board of Directors of the Company since February 1997. He is responsible for corporate and scientific planning and serves as our liaison to the clinical and academic medical community.

Dr. Arquilla innovatively obtained the very first patent for a pregnancy test in 1964. Dr. Arquilla has been a full time faculty member of the Departments of Pathology at the University of Southern California (USC), the University of California at Los Angeles (UCLA) and the University of California at Irvine (UCI) respectively (1959-1994). He was a Professor and Chair of Pathology at UCI Chief of Pathology services at UCI Medical Center from 1968 until 1986. He also established the UCI Pathology referral services. He has been an active interest in applying immunology to diagnostic test throughout the past fifty years and was among the first to develop immunological tests to measure levels of proteins and hormones.

Dr. Arquilla has been a very active member of the American Diabetes Association and the Juvenile Diabetes Foundation International. He has published over 80 scientific articles. He received a B.S. degree from Northern Illinois University in 1947, an M.S. in Physiology from the University of Illinois in 1949, and M.D. from Western Reserve University in 1955 and a Ph.D. in Anatomy from Western Reserve University in 1957. Dr. Arquilla completed his residency in Pathology in 1959 and received his Board Certification in Anatomic Pathology in 1963.

Mr. Jia has over 10 years of investment banking, venture capital, marketing institutional trading and senior corporate management experience. Mr. Jia is familiar with all procedures for manufacturing and marketing with respect to the Asia pharmaceutical market, and has an in-depth understanding of the industry.

Over the past few years, Mr. Jia has helped several Chinese domestic pharmaceutical companies list and obtain financing in the China stock exchange market (Shenzhen) and in Hong Kong. Prior to founding Jade Capital Group Ltd and Jade Pharmaceutical Inc., Mr. Jia served as Marketing Director for China Real Estate Corporation, one of the largest Chinese property corporations, between 1999 and 2003. Between 1989 and 1998, Mr. Jia served as General Manager of several branches of China Resource Co. Ltd (CRC), the largest China export and import corporation. From 1987 to 1989, Mr. Jia worked for the China National Machinery import and export corporation where he served as Manager of the Import Department for Medical Instruments.

In addition to his business and entrepreneurial activities, Mr. Jia is a Senior Editor of China Finance. Mr. Jia is fluent in Mandarin, Cantonese, English and Vietnamese. Mr. Jia received his B.A. in economics from the University of International Business and Economics of China in 1987.